Skip to main content

Free Content Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain

Download Article:
(PDF 62.4 kb)


The aim of this study was to determine the proportion of antituberculosis ofloxacin resistance among Mycobacterium tuberculosis strain isolates in Spain. Over a period of one month, 213 M. tuberculosis strains collected from 14 different hospitals were studied, including strains both susceptible and resistant to primary anti-tuberculosis drugs. In 28.1% of the strains, a minimum inhibitory concentration (MIC) for ofloxacin of 0.25 μg/ml was obtained; in 43.6% the MIC was 0.5 μg/ml; in 22.06% it was 1 μg/ml; and in 6.1% it was ≥2 μg/ml. Ofloxacin currently seems to be an effective antimicrobial in vitro against susceptible or multiresistant strains of M. tuberculosis in human immunodeficiency virus (HIV)-negative or HIV-positive patients in Spain.

Keywords: in vitro susceptibility; ofloxacin; tuberculosis

Document Type: Short Communication

Affiliations: 1: Mycobacteria Reference Laboratory, Cordoba, Spain 2: Hoechst Marion Roussel, Barcelona, Spain

Publication date: June 1, 2000

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more